RYHTY (Ryman Healthcare) Research & Development: $0.0 Mil (TTM As of Mar. 2025)


RYHTY Ryman Healthcare Ltd RYHTY
70 GF Score
Price $6.11
GF Value $17.68
! 2 Warning Signs
View Full Analysis

What is Ryman Healthcare Research & Development?

Ryman Healthcare RYHTY -12.82% 70 Research & Development is $0.0 Mil as of Mar. 2025. GuruFocus rates RYHTY with a GF Score™ of 70/100 and a GF Value™ of $17.68. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ryman Healthcare's Research & Development for the six months ended in Mar. 2025 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was $0.0 Mil.

Ryman Healthcare  (OTCPK:RYHTY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ryman Healthcare Research & Development Related Terms

Ryman Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Ryman Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryman Healthcare Research & Development Chart

Ryman Healthcare Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ryman Healthcare Semi-Annual Data
Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RYHTY
70GF Score
Ryman Healthcare Ltd RYHTY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryman Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
Ryman Healthcare (RYHTY) has a Research & Development of $0.0 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Ryman Healthcare and its competitors.
Is Ryman Healthcare's Research & Development too high?
Ryman Healthcare's current Research & Development is $0.0 Mil. Overall, Ryman Healthcare has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Ryman Healthcare's Research & Development compare to HCA and THC?
Ryman Healthcare's Research & Development of $0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ryman Healthcare and its competitors. Ryman Healthcare's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryman Healthcare stock overvalued right now?
Ryman Healthcare (RYHTY) has a current Research & Development of $0.0 Mil. The stock's GF Value™ is $17.68, compared to a current price of $6.11 — trading 65.4% below its estimated fair value. The current Research & Development is $0.0 Mil. Ryman Healthcare's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ryman Healthcare (RYHTY), the current Research & Development is $0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryman Healthcare (RYHTY) Overvalued in 2026?

Based on GuruFocus' analysis, Ryman Healthcare stock appears to be undervalued. The current stock price of $6.11 is trading 65.4% below its estimated GF Value™ of $17.68.

Key valuation signals for RYHTY:

  • Research & Development: $0.0 Mil
  • GF Value™: $17.68 vs. price of $6.11 (65.4% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the RYHTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryman Healthcare Business Description

Address 92 Russley Road, P.O. Box 771, Christchurch, CT, NZL, 8042
Ryman Healthcare Ltd is a retirement living and aged care provider operating in New Zealand and Australia. It owns and operates integrated retirement villages through its trading subsidiaries, which operate in the aged care and retirement living sector in New Zealand and Australia. The Group operates in a single industry: the provision of integrated retirement living and aged care for older people in New Zealand and Australia. The majority of revenue is derived from Care and village fees, which relate to the provision of accommodation, care and related services to aged care residents and retirement living residents.
70GF Score

Get the complete analysis for RYHTY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price
$17.68
GF Value